Castle biosciences announces preliminary q4 and fy 2019 performance results

Castle biosciences announces preliminary fourth quarter and full-year 2019 performance results, delivering 29% decisiondx-melanoma test report volume growth in 2019.castle biosciences inc - q4 decisiondx-melanoma test report volume increased 37% compared to q4 2018.castle biosciences inc - new ordering clinicians for decisiondx-melanoma increased 24% in 2019 compared to 2018.castle biosciences inc - year-end 2019 cash and cash equivalents balance of about $99 million.castle biosciences - delivered 4,480 decisiondx-melanoma test reports in q4, compared to 3,270 reports during q4 of 2018.castle biosciences - delivered 434 decisiondx-um test reports in q4, compared to 385 reports during q4 of 2018.
CSTL Ratings Summary
CSTL Quant Ranking